View Older Stories View More Recent Stories

Apr 9, 2024 08:30AM NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Jan 9, 2024 08:45AM NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
Dec 27, 2023 05:00PM Neurosense Therapeutics (NRSN) Receives Nasdaq Non-compliance Notice
Dec 27, 2023 05:00PM NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
Dec 14, 2023 09:25AM Neurosense Therapeutics (NRSN) Reports Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
Dec 14, 2023 09:24AM NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
Dec 4, 2023 04:02PM Neurosense Therapeutics (NRSN) to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5
Dec 4, 2023 04:01PM NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Nov 28, 2023 08:45AM NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Nov 13, 2023 09:20AM Neurosense Therapeutics (NRSN) Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Nov 13, 2023 09:20AM NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Nov 9, 2023 09:00AM NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Nov 6, 2023 08:30AM NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
Nov 1, 2023 09:00AM NeuroSense Therapeutics to Participate in BIO-Europe Fall
Oct 17, 2023 08:31AM Neurosense Therapeutics (NRSN) CEO Issues Q3 2023 Update
Oct 17, 2023 08:30AM NeuroSense CEO Provides Q3 2023 Update
Oct 4, 2023 09:11AM Neurosense Therapeutics' (NRSN) PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
Oct 4, 2023 09:10AM NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
Oct 3, 2023 07:00AM Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
Oct 2, 2023 08:47AM Neurosense Therapeutics (NRSN) Ends its At-The-Market Equity Offering Program
Oct 2, 2023 08:46AM NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
Sep 20, 2023 09:05AM Neurosense Therapeutics (NRSN) Granted SME Status by EMA
Sep 20, 2023 09:05AM European Medicines Agency Grants NeuroSense SME Status
Sep 19, 2023 09:04AM Neurosense Therapeutics (NRSN) Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Sep 19, 2023 09:00AM NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Sep 14, 2023 09:00AM NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
Sep 6, 2023 08:30AM NeuroSense to Host Investor Webinar on September 12, 2023
Aug 16, 2023 09:00AM NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
Jul 17, 2023 08:30AM NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
Jul 11, 2023 09:00AM NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
Jul 6, 2023 08:30AM NeuroSense CEO Provides Q2 2023 Update
Jun 22, 2023 08:30AM Neurosense Therapeutics (NRSN) Prices 3M Share Offering at $1.50/sh
Jun 22, 2023 08:30AM NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
Jun 1, 2023 08:45AM Neurosense Therapeutics (NRSN) Reports Q1, Provides Business Update
Jun 1, 2023 08:45AM NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
May 15, 2023 09:05AM NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
May 2, 2023 08:35AM Neurosense Therapeutics (NRSN) Reports Positive Preliminary Results in Parkinson's Biomarker Study
May 2, 2023 08:30AM NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
Apr 17, 2023 09:06AM Neurosense Therapeutics (NRSN) CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
Apr 17, 2023 09:05AM NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
Mar 27, 2023 09:15AM NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
Mar 23, 2023 09:05AM NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Mar 22, 2023 09:28AM NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
Mar 16, 2023 08:30AM NeuroSense Therapeutics to Participate in BIO-Europe Spring
Feb 13, 2023 08:30AM NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
Feb 9, 2023 09:20AM Neurosense Therapeutics (NRSN), QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
Feb 9, 2023 09:20AM NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
Feb 8, 2023 09:14AM Neurosense Therapeutics (NRSN) Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
Feb 8, 2023 09:14AM NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
Feb 6, 2023 09:12AM Neurosense (NRSN) Expands Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND
View More Recent Stories View Older Stories